



## Spruce Biosciences Recognized as a Bay Area Best Place to Work

June 6, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2024-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a [Best Place to Work](#) in 2024.

"We are thrilled to be named as a *Best Place to Work* in the Bay Area, which is a testament to our unwavering dedication to cultivating a mission-driven company culture underlying our core values of trust, innovation, ownership and diversity," said Javier Swarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences. "Our team members are at the heart of our organization, and I'm immensely proud of their dedication and commitment to each other and our stakeholders. This recognition deepens our sense of purpose as we advance our efforts towards delivering transformative treatment options for underserved patient communities."

Winning organizations were selected from over 230 competing Bay Area companies that have created exceptional workplaces that their employees value highly. The selection process was based on anonymous employee surveys with participation requirements and overall employee engagement score rankings. Applicants were evaluated and ranked across workplace factors and values, including collaborative culture, compensation and benefits offerings, other amenities, and management practice, according to the number of Bay Area employees.

### About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF<sub>1</sub> receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visit [www.sprucebio.com](http://www.sprucebio.com) and follow us on X @[Spruce\\_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### About 2024 Bay Area Best Places to Work

Best Places to Work is an innovative publication and awards program produced by the San Francisco Business Times and the Silicon Valley Business Journal. The survey was administered online by the employers and through a service provided by Quantum Workplace, our research partner. The rankings are numeric based on Quantum's scoring process and determined by surveys that went directly to employees who answered a series of questions. By ranking companies and sharing best practices we facilitate idea sharing and help other companies learn from the best.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240606309168/en/): <https://www.businesswire.com/news/home/20240606309168/en/>

### Media

Katie Beach Oltsik  
Inizio Evoke Comms  
(937) 232-4889  
[Katherine.Beach@inizioevoke.com](mailto:Katherine.Beach@inizioevoke.com)  
[media@sprucebio.com](mailto:media@sprucebio.com)

### Investors

Samir Gharib  
President and CFO  
Spruce Biosciences, Inc.  
[investors@sprucebio.com](mailto:investors@sprucebio.com)

Source: Spruce Biosciences, Inc.